Rigel Pharmaceuticals is a biotechnology company based in South San Francisco, CA, dedicated to the discovery, development, and provision of innovative therapies that significantly enhance the lives of patients with hematologic disorders and cancer.
The company's pipeline includes proprietary programs such as IRAK1 and RIPK1, as well as partnered programs with leading pharmaceutical companies like BerGenBio, Daiichi-Sankyo, Grifols, Kissei Knight, Lilly, Medison, and Novo Nordisk. Rigel Pharmaceuticals is committed to developing novel treatments, including TAVALISSE for thrombocytopenia in adult patients with chronic immune thrombocytopenia and REZLIDHIA for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.
Generated from the website